Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Stanley Riddell
Fred Hutchinson Cancer Research Center, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Juno Therapeutics
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
This project involves conducting research on patients with ROR1 positive cancers by adoptively transferring T cells that are genetically engineered to recognize ROR1, and designing new receptors to improve efficacy. The approach has been licensed by the institution to Juno Therapeutics. The value of Dr. Riddell’s financial interests in Juno could be impacted depending on the outcome of this research.
TARGETING ROR1 WITH CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
PUBLIC HEALTH RELEVANCE STATEMENT (PROJECT NARRATIVE) Despite improvements in diagnosis and treatment, cancers that are refractory to chemotherapy remain a common cause of death. Immunotherapy, including the administration of antibodies that target malignant cells or immune checkpoints, and the adoptive transfer of tumor-reactive T cells provides a new option for patients with even the most refractory malignancies. We have identified ROR1 as a candidate target for immunotherapy on many human cancers and designed receptors that can redirect the patient's T cells to kill ROR1 positive tumors. In this proposal, we will treat patients with ROR1 positive cancers by adoptively transferring T cells that are genetically engineered to recognize ROR1, and design new receptors to improve efficacy.
Filed on July 26, 2016.
Tell us what you know about Stanley Riddell's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Stanley Riddell filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | >$600,000 |
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | $60,000 - $79,999 |
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | $60,000 - $79,999 |
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | Value cannot be readily determined |
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | Value cannot be readily determined |
| Stanley Riddell | Fred Hutchinson Cancer Research Center | Conflict of Interest | Juno Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.